Series date: 
10/01/2019 - 12:00pm EDT to 12/31/2023 - 1:30pm EST

Personalized medicine helps doctors learn about a person’s genetic makeup and how their tumor grows.  This tumor board discussion will provide an update in the state of the art treatment of oral, head and neck cancers. In addition, “Hot Topics” in immunotherapy, HPV related cancers, thyroid cancer, and proton therapy will be discussed.

Medical Oncologists, Radiation Oncologists, Otolaryngologists, Surgeons, Radiologists, Hematologists, Pathologists, Plastic Surgeons and Oral and Maxillofacial Surgeons.

•    Improve clinical decision making, clinical outcomes, and patient experience via a multidisciplinary team approach. Group discussion include prospective patient care management, national treatment guidelines, staging, and options and eligibility for genetic testing, clinical research studies, and supportive care services.

•    Develop a comprehensive treatment plan for head and neck oncology patients leveraging imaging and pathology testing results and meet Commission on Cancer accreditation standards compliance


Guilherme Rabinowits, M.D. 
Head and Neck and Cutaneous Medical Oncology
Co-Leader, Head and Neck Disease Management Team
Miami Cancer Institute
Miami, Florida

Geoffrey Young, M.D., Ph.D., FACS, FSSO
Chief – Head and Neck Surgery
Miami Cancer Institute
Vice Chair – Surgery
Florida International University

Guilherme Rabinowits, M.D., indicated that he is a consultant for Emd Serono, Pfizer, Regeneron, Sanofi, Castle and Merck.  He is also a stock/shareholder with Regeneron, and Syros Pharmaceuticals and has indicated that the presentations  or discussions  will not include off-label or unapproved product usage.

Geoffrey Young, M.D., Ph.D., has indicated that he does not have any relevant relationships with ineligible companies* to disclose and has indicated that the presentations  or discussions  will not include off-label or unapproved product usage.

 All of the relevant financial relationships listed for this/these individual have been mitigated.

Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose with ineligible companies*

*Ineligible companies - Companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Disclosure Policy and Disclaimer

Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.

Baptist Health South Florida designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


American Board of Surgery - Maintenance of Certification (MOC) - Accredited CME - Complex General Surgical Oncology

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

Successful completion of this course is submitted to specialty boards through the ACCME's PARS system. 

Series location: 
Baptist Hospital
8900 N. Kendall Dr
Miami, FL 33176
United States


Sessionsort ascending Date
Head and Neck Tumor Board 04/21/2022 - 12:00pm to 1:30pm EDT
Head and Neck Tumor Board 01/06/2021 - 12:00pm to 1:30pm EST